For Patients, By Patients: Your Guide to Lorlatinib
Following the pivotal CROWN study, more people in our ALK-positive lung cancer community are starting lorlatinib—either as their first-line treatment or after other therapies. Managing side effects can feel daunting, but you’re not alone. In a first-of-its-kind collaboration, ALK Positive’s Vice President Nancee Pronsati and Director of Clinical & Research Affairs Dr. Ken Culver teamed up with world-renowned physicians and patient advocates to co-author a practical, patient-centered guide published in ScienceDirect.
This article offers clear, actionable guidance on what to expect with lorlatinib, how to manage side effects, and how to protect your quality of life—so you can stay on treatment and continue living fully. Below, we’ve summarized the key takeaways from this important resource.
For the full guide, including tips, timelines, and patient perspectives, click here to read the article on ScienceDirect.
